Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Fennec Pharmaceuticals (FENC) Equity Ratio (2016 - 2025)

Fennec Pharmaceuticals' Equity Ratio history spans 15 years, with the latest figure at 0.5 for Q4 2025.

  • For the quarter ending Q4 2025, Equity Ratio rose 484.85% year-over-year to 0.5, compared with a TTM value of 0.5 through Dec 2025, up 484.85%, and an annual FY2025 reading of 0.5, up 484.85% over the prior year.
  • Equity Ratio for Q4 2025 was 0.5 at Fennec Pharmaceuticals, up from 0.09 in the prior quarter.
  • The five-year high for Equity Ratio was 0.9 in Q1 2021, with the low at 0.53 in Q3 2023.
  • Average Equity Ratio over 5 years is 0.09, with a median of 0.09 recorded in 2024.
  • Biggest YoY gain for Equity Ratio was 484.85% in 2025; the steepest drop was 674.05% in 2025.
  • Tracing FENC's Equity Ratio over 5 years: stood at 0.73 in 2021, then plummeted by 113.05% to 0.1 in 2022, then tumbled by 353.66% to 0.43 in 2023, then surged by 69.8% to 0.13 in 2024, then skyrocketed by 484.85% to 0.5 in 2025.
  • Per Business Quant, the three most recent readings for FENC's Equity Ratio are 0.5 (Q4 2025), 0.09 (Q3 2025), and 0.17 (Q2 2025).